Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omecamtiv mecarbil for exercise capacity in heart failure with reduced ejection fraction
NL-OMON55869Phase 3Active, not recruiting
- Sponsor
- Cytokinetics
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heart failure with reduced ejection fraction (HFrEF) comparing Omecamtiv mecarbil with Placebo (2 arms). Primary endpoint: Change in peak oxygen uptake. Started Jul 2020; status: active, not recruiting.
02
Drugs
omecamtiv mecarbil
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NL-OMON55869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55869.